Converge Consulting, LLC

Based in the US, Converge Consulting, LLC provides strategic and operational expertise tailored for the Life Sciences sector, assisting organizations throughout various stages of the drug development lifecycle. Converge Consulting, LLC specializes in offering consulting services for the Life Sciences industry. The firm is headquartered in Cambridge, US. It has been involved in 1 deal, with the most recent deal occurring on September 18, 2025.

The founder's history and previous ventures are not publicly available. Converge Consulting specializes in providing strategic, operational, and execution expertise tailored exclusively for the Life Sciences industry. The company offers a comprehensive suite of services aimed at assisting organizations through various phases of the Life Sciences lifecycle, including preclinical, clinical, commercial, and mature stages. Their core offerings encompass CMC Services, which involve chemical and process engineering to support drug development, as well as supply chain expertise, operational excellence, and quality management system design.

Converge Consulting collaborates with a diverse client base that includes biotech, pharmaceutical companies, and emerging biopharmaceutical firms, focusing on addressing their unique challenges related to regulatory compliance, commercial launch readiness, and operational efficiency. The firm operates primarily in North America and Europe, serving clients in key markets such as the United States, Canada, the United Kingdom, and Germany. Converge Consulting generates revenue through service agreements structured around project-based engagements and long-term partnerships with its clients in the Life Sciences sector. Transactions typically involve the provision of consulting services that address specific client needs, such as supply chain optimization, regulatory compliance support, and quality management system implementation.

The pricing structure is determined by the scope and scale of the services provided, with potential engagement models including retainer agreements for ongoing consulting support and fee-for-service billing for specific projects. The firm’s flagship services, particularly in CMC and operational excellence, are integral to their revenue model, reflecting the critical nature of these services in the drug development and commercialization processes. In September 2025, Dark Horse Consulting Group, Inc. , a portfolio company of WestView Capital Partners and Arcline Investment Management, acquired Converge Consulting, LLC.

The acquisition enables Dark Horse Consulting Group, Inc. to expand its platform capabilities. Future growth initiatives include potential expansion into new geographic markets, although specifics on these plans have not been disclosed.